Karyopharm Therapeutics Inc. 8-K

What Happened

• Karyopharm Therapeutics Inc. announced on March 24, 2026 that it entered a Securities Purchase Agreement with RA Capital Management; the related private placement closed on March 26, 2026 and generated gross proceeds of approximately $30 million (before placement agent fees and offering expenses).
• In addition, in March 2026 the company sold 2,994,441 shares of common stock under its Jefferies Open Market Sale Agreement for net proceeds of about $19.8 million. Combined, these transactions raise roughly $49.8 million in new capital.

Key Details

• Private Placement: 1,030,354 shares of common stock sold at $6.785 per share and, in lieu of shares, pre-funded warrants to purchase up to 3,391,164 shares at $6.7849 per pre-funded warrant; also issued accompanying warrants to buy 4,421,518 shares at an exercise price of $10.00 per share.
• ATM sales: 2,994,441 shares sold under the Jefferies Open Market Sale Agreement (includes 1,100,844 shares previously disclosed); net proceeds ≈ $19.8 million.
• Post-closing capital structure: 22,543,316 shares of common stock outstanding and pre-funded warrants to purchase an aggregate of 4,005,556 shares outstanding.
• Timing: Securities Purchase Agreement executed March 24, 2026; private placement closed March 26, 2026.

Why It Matters

• The financings provide near-term liquidity: Karyopharm states its cash, cash equivalents, investments and expected operating cash flow should fund current plans into late Q3 2026.
• These transactions dilute existing shareholders to the extent warrants are exercised and new shares were issued, while providing the company with additional capital to advance operations and obligations.
• Investors should note the types of securities issued (common shares, pre-funded warrants, and $10 exercise warrants), the reported gross/net proceeds, and the updated share and warrant counts when assessing ownership and potential future dilution.